Travis M. Figg

Array ( [id] => 20607104 [patent_doc_number] => 12582683 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Prostate neoantigens and their uses [patent_app_type] => utility [patent_app_number] => 18/342322 [patent_app_country] => US [patent_app_date] => 2023-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 772090 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18342322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938214 [patent_doc_number] => 20240033353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => CD70 COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 18/334582 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050891 [patent_doc_number] => 20240092860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS [patent_app_type] => utility [patent_app_number] => 18/332366 [patent_app_country] => US [patent_app_date] => 2023-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18332366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861932 [patent_doc_number] => 20230416367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/330141 [patent_app_country] => US [patent_app_date] => 2023-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18330141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895246 [patent_doc_number] => 20240010731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => COMBINATION PRODUCT FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/328707 [patent_app_country] => US [patent_app_date] => 2023-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18328707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830890 [patent_doc_number] => 20230399415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => Twin Immune Cell Engager [patent_app_type] => utility [patent_app_number] => 18/326248 [patent_app_country] => US [patent_app_date] => 2023-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971965 [patent_doc_number] => 20240052057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies [patent_app_type] => utility [patent_app_number] => 18/322846 [patent_app_country] => US [patent_app_date] => 2023-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003678 [patent_doc_number] => 20240067749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => ANTIBODIES BINDING TO GPRC5D [patent_app_type] => utility [patent_app_number] => 18/309037 [patent_app_country] => US [patent_app_date] => 2023-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18309037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610909 [patent_doc_number] => 20230277639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => PERSONALIZED VACCINE [patent_app_type] => utility [patent_app_number] => 18/299858 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27351 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657762 [patent_doc_number] => 20230303716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 18/298310 [patent_app_country] => US [patent_app_date] => 2023-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18298310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142546 [patent_doc_number] => 20240141389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => THERAPEUTIC GENOME EDITING IN WISKOTT-ALDRICH SYNDROME AND X-LINKED THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 18/296235 [patent_app_country] => US [patent_app_date] => 2023-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18844537 [patent_doc_number] => 20230406941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => Anti-AXL Antagonistic Antibodies [patent_app_type] => utility [patent_app_number] => 18/170929 [patent_app_country] => US [patent_app_date] => 2023-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18170929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610936 [patent_doc_number] => 20230277666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPRISING CO-STIMULATORY RECEPTOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/159887 [patent_app_country] => US [patent_app_date] => 2023-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19915219 [patent_doc_number] => 12290565 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers [patent_app_type] => utility [patent_app_number] => 18/056166 [patent_app_country] => US [patent_app_date] => 2022-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18315 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449624 [patent_doc_number] => 20230190900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => BISPECIFIC EGFR/CD16 ANTIGEN-BINDING PROTEIN [patent_app_type] => utility [patent_app_number] => 18/047917 [patent_app_country] => US [patent_app_date] => 2022-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18364173 [patent_doc_number] => 20230145764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => BLOOD-BASED TUMOR MUTATION BURDEN PREDICTS OVERALL SURVIVAL IN NSCLC [patent_app_type] => utility [patent_app_number] => 17/961827 [patent_app_country] => US [patent_app_date] => 2022-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451604 [patent_doc_number] => 20230192882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis [patent_app_type] => utility [patent_app_number] => 17/955743 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17955743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628268 [patent_doc_number] => 20230287123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => B7-H4 ANTIBODY DOSING REGIMENS [patent_app_type] => utility [patent_app_number] => 17/935805 [patent_app_country] => US [patent_app_date] => 2022-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351924 [patent_doc_number] => 20230140035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND THERAPY [patent_app_type] => utility [patent_app_number] => 17/935152 [patent_app_country] => US [patent_app_date] => 2022-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73500 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484992 [patent_doc_number] => 20230212308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ANTIBODIES BINDING TO GPRC5D [patent_app_type] => utility [patent_app_number] => 17/935017 [patent_app_country] => US [patent_app_date] => 2022-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935017 [rel_patent_id] =>[rel_patent_doc_number] =>)